CONGRESSES

Our medical oncologists and laboratory investigators are regular speakers and organizers of some of the most important international seminars and scientific meetings.

We have presented the results of our investigations into the causes of cancer and novel treatments at some of the most important national and international oncology congresses.

BROWSE CONGRESSES
BY YEAR

IASLC 15th World Congress on Lung Cancer (WCLC)

DATE27/10/2013 - 31/10/2013

PLACESydney, Australia

The Spanish Lung Cancer Group (SLCG) BRCA1-RAP80 Expression Customization (BREC) randomized phase III trial of customized chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients with wild-type epidermal growth factor receptor (EGFR) (NCT00617) Rosell R, MD, PhD

24th International Congress on Anti-Cancer Treatment (ICACT)

DATE05/02/2013 - 06/02/2013

PLACEParis, France

Understanding adaptive resistance in EGFR mutant NSCLC: Deconstructing the myth of T790M Rosell R, MD, PhD

Molecular based decision making for personalized cancer management Rosell R, MD, PhD

37th Congress of the European Society of Medical Oncology

DATE28/09/2012 - 02/10/2012

PLACEVienna, Austria

Concomitant actionable mutations and overall survival (OS) in EGFR-mutant non-small-cell lung cancer (NSCLC) patients (p) included in the EURTAC trial: EGFR exon 19 del/L858R w/ or w/out EGFR T790M, TP53, EML4-ALK and BIM mRNA expression Rosell R, MD, PhD

American Society of Clinical Oncology (ASCO) Annual Meeting

DATE01/06/2012 - 05/06/2012

PLACEChicago, U.S.A.

EFGR compound mutants discriminate survival to erlotinibin non-small-cell lung cancer (NSCLC) patients (p) in the EURTAC study Rosell R, MD, PhD

Retrospective EGFR mutation testing of clinical specimens from the EURTAC trial of erlotinib in non-small-cell lung cancer (NSCLC) using a novel allele-specific PCR (AS-PCR) assay Benlloch S, PhD

Metastatic Melanoma - Oncogenic lesions and dysregulation of canonical signaling pathways – clinical intervention

DATE26/04/2012

PLACEUSP Hospital Dexeus, Barcelona, Spain

Oncogenic driver mutations in melanoma and other tumors: new opportunities for combinatory therapies Rosell R, MD, PhD

Is there still room for chemotherapy in lung cancer? Lessons from EGFR-driven cancer González Cao M, MD

BRAF mutations in cfDNA in blood: lessons from EGFR mutations in cfDNA Molina M.D, PhD